What Emerging Myeloma Treatments Are Showing Promise? – Patient Empowerment Network
Dr. Mark Schroeder reviews the latest advances in myeloma treatment, including a discussion of CAR T-cell therapy and bispecific antibodies.
Related Articles
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
University program puts Missouri school in world’s top 10
MISSOURI (KSNF) — One university in the Show-Me State receives high marks on a global scale. Washington University in St. Louis (WUSTL) is ranked 8th…
In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms – John T. Milliken Department of Medicine
Study in Blood dissecting the role of NFκB signaling effectors in MPN disease biology Stephen T. Oh, MD, PhD, Co-Chief and Associate Professor of Medicine,…
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans
Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However,…
Blues announce 25th Anniversary Hockey Fights Cancer Night initiatives for Dec. 12 | St. Louis Blues
ST. LOUIS – The St. Louis Blues are preparing to recognize the 25th Anniversary of the National Hockey League’s fight against cancer when they host…
WashU Expert: Some parasites turn hosts into ‘zombies’ – The Source – Washington University in St. Louis
While the flesh-eating undead portrayed on television are just fiction, there are clear examples of parasites that have evolved to manipulate their hosts, according to…